A Study of DF6002 Alone and in Combination With Nivolumab

Inclusion Criteria:

• Advanced/metastatic solid tumors, for which no standard therapy exists or standardtherapy has failed among the following tumor types: melanoma, non-small cell lungcancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric,esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cellcarcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate

• ECOG performance status of 0 or 1

• Clinical or radiological evidence of disease

• Adequate hematological, hepatic and renal function

• Anticoagulants are required for the following: Khorana Risk Score ≥ 2 or as assessedby Investigator as being at high risk for venous thromboembolism (VTE) or history ofVTE ≥ 6 months from enrollment

Exclusion Criteria:

• Concurrent anticancer treatment (with the exception of palliative bone directedradiotherapy), immune therapy, or cytokine therapy (except for erythropoietin),major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy withsteroids or other immunosuppressive agents, or use of any investigational drugwithin 28 days before the start of study treatment

• Prior treatment with DF6002, recombinant human interleukin-12 (rhIL-12)-directedtherapy, or any drug containing an interleukin-12 (IL-12) moiety

• Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin,localized prostate cancer or cervical carcinoma in situ

• Rapidly progressive disease

• Serious cardiac illness or medical conditions

• Known diagnosis of antiphospholipid syndrome or clinically significant hereditarythrombophilia

Other protocol-defined inclusion/exclusion criteria apply